Clinical trial
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
NCT04038502
Study timeline
Study start (actual)2019-10-01Date precision: day
Registry last updated2026-09-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Interventions
CarboplatinDRUG · verified · RxNorm: carboplatin
OlaparibDRUG · verified · RxNorm: olaparib
Sponsors & collaborators
VA Office of Research and Developmentlead sponsor
Mapped research locations
New YorkNew York, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1SeattleWashington, United States1PortlandOregon, United States1DurhamNorth Carolina, United States1Washington D.C.District of Columbia, United States1MinneapolisMinnesota, United States1OrlandoFlorida, United States1AuroraColorado, United States1Ann ArborMichigan, United States1The BronxNew York, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04038502 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.